Adenosine Kinase Deficiency Disrupts the Methionine Cycle and Causes Hypermethioninemia, Encephalopathy, and Abnormal Liver Function  by Bjursell, Magnus K. et al.
ARTICLE
Adenosine Kinase Deficiency Disrupts the Methionine Cycle
and Causes Hypermethioninemia, Encephalopathy,
and Abnormal Liver Function
Magnus K. Bjursell,1,2 Henk J. Blom,3 Jordi Asin Cayuela,4 Martin L. Engvall,2,5,6 Nicole Lesko,6,7
Shanti Balasubramaniam,8 Go¨ran Brandberg,9 Maria Halldin,10 Maria Falkenberg,11 Cornelis Jakobs,3
Desiree Smith,3 Eduard Struys,3 Ulrika von Do¨beln,6,7 Claes M. Gustafsson,11 Joakim Lundeberg,12
and Anna Wedell1,2,6,*
Four inborn errors of metabolism (IEMs) are known to cause hypermethioninemia by directly interfering with the methionine cycle.
Hypermethioninemia is occasionally discovered incidentally, but it is often disregarded as an unspecific finding, particularly if liver
disease is involved. In many individuals the hypermethioninemia resolves without further deterioration, but it can also represent an
early sign of a severe, progressive neurodevelopmental disorder. Further investigation of unclear hypermethioninemia is therefore
important. We studied two siblings affected by severe developmental delay and liver dysfunction. Biochemical analysis revealed
increased plasma levels of methionine, S-adenosylmethionine (AdoMet), and S-adenosylhomocysteine (AdoHcy) but normal or mildly
elevated homocysteine (Hcy) levels, indicating a block in the methionine cycle. We excluded S-adenosylhomocysteine hydrolase
(SAHH) deficiency, which causes a similar biochemical phenotype, by using genetic and biochemical techniques and hypothesized
that there was a functional block in the SAHH enzyme as a result of a recessive mutation in a different gene. Using exome sequencing,
we identified a homozygous c.902C>A (p.Ala301Glu) missense mutation in the adenosine kinase gene (ADK), the function of which fits
perfectly with this hypothesis. Increased urinary adenosine excretion confirmed ADK deficiency in the siblings. Four additional individ-
uals from two unrelated families with a similar presentation were identified and shown to have a homozygous c.653A>C (p.Asp218Ala)
and c.38G>A (p.Gly13Glu) mutation, respectively, in the same gene. All threemissensemutations were deleterious, as shown by activity
measurements on recombinant enzymes. ADK deficiency is a previously undescribed, severe IEM shedding light on a functional link
between the methionine cycle and adenosine metabolism.Introduction
Hypermethioninemia can indicate a severe underlying
genetic disorder, but it can also result from a benign
inborn error of metabolism (IEM) or have a nongenetic
cause. Four IEMs are known to cause hypermethionine-
mia by directly interfering with methionine or homo-
cysteine metabolism. Methionine (Met) is normally con-
verted to homocysteine (Hcy) in three enzymatic steps
(Figure 1). Methionine adenosyltransferase (MAT) I/III
deficiency (MIM 250850) affects the first step, the transfer
of an adenosyl group from ATP to Met, which normally
generates S-adenosylmethionine (AdoMet).1 MAT I/III
deficiency is clinically benign in most cases. Glycine-N-
methyltransferase (GNMT) is one of about 60 methyl-
transferases that have been identified in mammals and
that rely on AdoMet for methyl group donation. GNMT
deficiency (MIM 606664) affects the quantitatively impor-
tant methylation of glycine to form sarcosine2 and
thereby results in AdoMet accumulation. Affected individ-1Department of Molecular Medicine and Surgery, Science for Life Laboratory
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The Americuals reported so far have shown discrete clinical symp-
toms, mainly from the liver. S-adenosylhomocysteine
hydrolase (SAHH) deficiency (MIM 613752) affects the
normal hydrolysis of S-adenosylhomocysteine (AdoHcy)
to Hcy and adenosine and causes a severe clinical syn-
drome including myopathy, liver dysfunction, and
grossly abnormal psychomotor development.3 Finally,
cystathionine beta-synthase (CBS) deficiency (MIM
236200) disrupts the first step of the transsulfuration
pathway that normally degrades Hcy, and this disruption
causes homocysteinuria.4 The hypermethioninemia in
homocysteinuria due to CBS deficiency is believed to
result from remethylation of the excessive levels of Hcy
into Met.5 CBS deficiency is associated with dislocation
of the optic lenses, early thromboembolic events, skeletal
abnormalities, and mental retardation. In addition,
elevated Met levels can be seen in fumarylacetoacetate
hydrolase (FAH) deficiency (tyrosinemia type 1 [MIM
276700]) and citrullinemia type 2 (CTLN2) or citrin defi-
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Figure 1. The Methionine Cycle and Its Relationship with the
Adenosine/AMP Futile Cycle
Met is converted through AdoMet and AdoHcy to Hcy, which is
subsequently remethylated back to Met. AdoMet functions as
a methyl-group donor in a wide range of transmethylation reac-
tions. The thermodynamics of the SAHH reaction favors conden-
sation of adenosine and Hcy to produce AdoHcy; physiologically,
AdoHcy is hydrolyzed when adenosine and Hcy are removed,
and increased levels of adenosine therefore cause reversal of the
reaction.
Adenosine is phosphorylated by ADK to AMP, which can be
dephosphorylated back to adenosine by 50 nucleotidase. This
so-called futile cycle, which is disrupted in adenosine kinase defi-
ciency, is considered an important regulator of adenosine and
adenine nucleotide levels. MAT, GNMT, SAHH, and CBS are defi-
cient in previously known IEMs that directly interfere with the
methionine cycle and result in hypermethioninemia.
Abbreviations are as follows: ADK, adenosine kinase; AdoHcy,
S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; AMP,
adenine mononucleotide; CBS, cystathionine beta-synthase;
GNMT, glycine N-methyl transferase; Hcy, homocysteine; MAT,
methionine adenosyltransferase; Met, methionine; and SAHH,
S-adenosylhomocysteine hydrolase.of fumarylacetate are presumed to inhibit MAT III,
whereas in citrin deficiency, the mechanism in unknown.
Hypermethioninemia can also be seen in liver disease and
sometimes in low-birth-weight and premature children,
and in these cases it is often transient.5 The underlying
mechanisms for these forms are unclear. Met is included
in many neonatal screening programs that aim to
uncover CBS deficiency, and methods of establishing
and discriminating between the different genetic causes
of hypermethioninemia are essential because of the
specific treatment modalities that are available for the
different conditions and their drastically different prog-
noses.
Exome sequencing, i.e., targeted resequencing of all
protein-coding sequences in our genome, is revolution-
izing diagnostics in medical genetics. IEMs are ideal
targets because their biochemical nature provides a func-508 The American Journal of Human Genetics 89, 507–515, Octobertional context facilitating validation of encountered
genetic variants. We applied exome sequencing to two
siblings who were affected by severe developmental delay
and liver dysfunction and who also displayed hyperme-
thioninemia. Biochemical analysis revealed elevated
plasma levels of Met, AdoMet, and AdoHcy but normal
or mildly elevated levels of Hcy (tHcy). Deficiency of
SAHH, caused by mutations in AHCY (MIM 180960), is
known to cause a similar biochemical phenotype.3 We
excluded this diagnosis by using a combination of genetic
and biochemical techniques and hypothesized that the
siblings had a functional block in this enzymatic step as
a result of a recessive mutation in a different gene. Exome
sequencing revealed a homozygous mutation in ADK
(MIM 102750), the function of which fits perfectly with
this hypothesis. Two additional unrelated pairs of siblings
with a similar biochemical phenotype were subsequently
investigated and were found to have homozygous muta-
tions in the same gene.Subjects and Methods
Clinical Description
We studied two Swedish siblings, a boy born in 1987 and a girl
born in 1996, with persistent isolated hypermethioninemia,
severe developmental delay, and mild liver dysfunction. The
parents were reportedly nonconsanguineous and healthy. An
older male sibling had previous surgery due to congenital anal
atresia but was otherwise healthy.
In the neonatal period both individuals were evaluated for
failure to thrive, and the older brother was also investigated for
prolonged conjugated hyperbilirubinemia. At a few months of
age, hypotonia, profound psychomotor delay, and liver dysfunc-
tion were diagnosed in both affected children. The children later
developed dysmorphic features with macrocephalus, frontal boss-
ing, hypertelorism, and slender hands and feet. Epileptic seizures
with early debut (before age 3) were present in both cases. The
clinical course was thereafter similar in both individuals and was
characterized by global psychomotor delay with sparse or absent
language, slowly progressive muscular weakness, and muscle
wasting. Epilepsy consisting of both partial and generalized
seizures continued in the boy until adulthood and tended to be
poorly controlled by antiepileptic therapy. EEG investigations
showed slow background activity with diffuse multifocal dis-
charges in some instances and abundant spike slow-wave
complexes of high amplitude resembling Lennox-Gastaut in
others. The girl died during sleep at the age of 10 years and
9 months.
Laboratory investigations showed persistent isolated
hypermethioninemia in both children; maximum plasma Met
values were 455 and 886 mmol/liter, respectively (reference range:
15–35 mmol/liter). Further investigations showed that total plasma
Hcy (tHcy) levels were normal or slightly increased, thereby
excluding homocystinuria due to CBS deficiency. Both AdoMet
and AdoHcy were elevated (Table 1), making deficiency of MAT
I/III unlikely. SAHH deficiency was ruled out by sequence
analysis of AHCY and determination of enzyme activity in fibro-
blasts from the affected individuals. Tests showed abnormal liver
function, including a moderate increase of liver transaminases7, 2011
Table 1. Clinical and Biochemical Characteristics of the Three Families with ADK Deficiency
Swedish Family Malaysian Family 1 Malaysian Family 2
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
Sex male female male male male female
Birth year 1987 1996 1992 1999 2000 2003
Met, plasma (mmol/liter) 455 (ref. 15–35) 886 800 (ref. 13–45) 550 800 600
Met, CSF (mmol/liter) 44 (ref. < 5) 41 n.a. n.a. n.a. n.a.
AdoMet, plasma (nmol/
liter)
677 (ref. 55–116) 496 153 335 303 656
AdoMet, CSF (nmol/liter) 264 (ref. 127–259) 291 n.a. n.a. n.a. n.a.
AdoHcy, plasma (nmol/
liter)
122 (ref. 9–45) 102 40 70 61 92
AdoHcy, CSF (nmol/liter) 102 (ref. 1–29) 68 n.a. n.a. n.a. n.a.
tHcy plasma (mmol/liter) 9.7 (ref. 5–15) 15 14.7 (ref. 5.5–17) 6 26 18
Adenosine, urine
(mmol/mol creatinine)
7.1 (ref. < 1) 9.9 (ref. < 2) n.a. n.a. n.a. n.a.
Inosine, urine (mmol/mol
creatinine)
2.7 (ref. < 3) 3.6 n.a. n.a. n.a. n.a.
Xanthine, urine (mmol/
mol creatinine)
6.8 (ref. < 30) 4.9 (ref. < 80) n.a. n.a. n.a. n.a.
Uric acid, plasma (mmol/
liter)
469 (ref. 230–480) 321 (ref. 155–350) n.a. n.a. n.a. n.a.
Prolonged conjugated
hyperbilirubinemia
þ n.a. þ þ þ þ
Alanine aminotransferase
(U/liter)
241 (ref. 0–37) 447 200 245 106 400
INR 1.7 (ref. < 1.2) 1.6 n.a. 1.1 1.3 1.4
CK (U/liter) 705 (ref. 0–250) 276 190 normal 300–400 130
Liver biopsy steatosis n.a. cholestasis cholestasis cholestasis n.a.
Macrocephalus/frontal
bossing
þ/þ þ/þ þ/þ /þ þ/þ þ/þ
Epilepsy/age at debut þ/1 yr þ/1 yr þ/2 y 11 mo þ/10 mo þ/16 mo þ/2 yr
Age at diagnosis 23 yr deceased at 10 y 9 mo 18 yr 11 yr 10 yr 7 yr
Maximum values are shown. Abbreviations are as follows: ref., reference value or range; AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; CK,
creatine kinase; CSF, cerebrospinal fluid; INR, international normalized ratio; Met, methionine; n.a., not analyzed; and tHcy, total plasma homocysteine.and an increased normalized ratio (INR), in both cases. Liver biop-
sies performed at 10months of age in the boy showed slight portal
fibrosis and steatosis. Magnetic resonance imaging (MRI) of the
brain showed cerebral atrophy with unspecific white-matter
degeneration and secondary dilated ventricular systems in the
boy. MRI of the brain was essentially normal at 14 months in his
sister.
When the suspicion of ADK deficiency was raised, we used this
information to identify four Malaysian individuals who were from
two unrelated families and had a similar biochemical phenotype
and clinical presentation (Table 1). These were two pairs of
siblings, and the parents were first cousins in both cases. All had
severe developmental delay and epilepsy, and all but one hadmac-
rocephalus with frontal bossing. Three individuals had cardiac
defects; subject 4 had mild pulmonary stenosis and a small secun-
dum atrial septal defect, subject 5 had a small secundum atrial
septal defect, and subject 6 had a mild coarctation of the aorta.The AmericTwo individuals had mild to moderate sensorineural hearing
loss. GNMT deficiency had been considered, but sequence analysis
of the corresponding gene did not reveal any pathogenic muta-
tions.
The Regional Ethics Committee at Karolinska Institutet
approved this study, and written informed consent was obtained
from the parents.Measurements of AdoMet and AdoHcy
AdoMet and AdoHcy in plasma and CSF were measured without
derivatization essentially as described.6 In brief, 500 ml of plasma
or CSF samples were deproteinized with perchloric acid, and
subsequently stable-isotope-labeled internal standards of both
AdoMet and AdoHcy were added to the clear supernatant. Stan-
dard curves with increasing amounts of the analytes and fixed
amounts of their internal standards were prepared for each set ofan Journal of Human Genetics 89, 507–515, October 7, 2011 509
samples. Analytes were extracted from the perchloric supernatant
via an anion-exchange solid-phase extraction procedure, and 10 ml
of the final eluate was injected onto the LC-MS/MS. The LC-MS/
MS, equipped with an electrospray interface, was operating in
the positive multiple-reaction monitoring mode. The intra assay
coefficients of variation for AdoMet and AdoHcy were <5%, and
the inter assay coefficients of variation for AdoMet and AdoHcy
were <8%.Assay of SAHH Activity in Fibroblasts
Skin fibroblasts from the two Swedish siblings were cultured in
Ham F10 supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin. Fibroblasts were harvested by trypsina-
tion and washed three times with Hanks buffered saline solu-
tion (HBSS). The cell pellet was resuspended and lysed in
200 ml of a 50 mM potassium phosphate buffer containing
0.1% lubrol (pH ¼ 7.4). The homogenate was centrifuged at
10,000 3 g at 4C for 10 min. The supernatant was kept on
ice and used for the enzyme assay and protein determination.
SAHH activity was measured by incubation of the homogenate
with 25 mM AdoHcy for 30 min at 37C and subsequent
measurement of the amount of formed Hcy formed by LC-
MS/MS (API3000, Applied Biosystems), essentially according to
AB Sciex protocols.Whole-Exome Sequencing
We used approximately 3–5 mg of genomic DNA from the two
Swedish siblings to prepare paired-end libraries according to
standard protocols supplied by Illumina (Illumina Inc., San
Diego, CA). The libraries were subjected to exome enrichment
via the in-solution SureSelect All Exon Kit (Agilent Technologies,
Santa Clara, CA). The enriched DNA libraries were sequenced
(2 3 76 bp) on a HiSeq 2000 sequencing system (Illumina).
The sequencing data were mapped to the canonical chromo-
somes (chromosomes 1–22, X, Y, and M; UCSC genome browser)
of the hg19 (GRCh37; downloaded from the UCSC genome
browser) reference human genome via Mosaik (v. 1.0.1388); up
to four mismatches were allowed. After removal of PCR dupli-
cates (MosaikDupSnoop) and reads without a unique mapping
location (MosaikSort), quality score recalibration and indel
realignment were performed with the GATK package. Variants
were extracted with the Maq model in SAMtools7 and filtered
by the following criteria: coverage R 83, consensus quality R
20, SNP quality R 20, and root-mean-square mapping quality
R 20. Identified variants were filtered against dbSNP build 131
(UCSC genome browser) and annotated on the basis of the
UCSC knownCanonical transcript database (UCSC genome
browser) via custom perl scripts. Any gene containing nonsynon-
ymous (NS) or splice-site (SS) variants or coding indels (I) was
considered a candidate gene under the dominant model. Under
the recessive model, genes containing one or more homozygous
or two or more heterozygous NS, SS, or I variants were consid-
ered candidate genes. An even more stringent homozygous
model, demanding at least one homozygous NS, SS, or I variant,
was also used. We used PolyPhen 2 to analyze the mutations
located in the candidate genes and predict their effects on the
protein.8,9Molecular Modeling
Images were obtained with the Molsoft MolBrowser 3.7-2a soft-
ware.510 The American Journal of Human Genetics 89, 507–515, OctoberCloning, Expression, and Purification of Wild-Type
and Mutant ADKs
Human ADK cDNA encoding the full-length protein (amino acids
1–345) and a C-terminal 63 His tag was optimized for expression
in bacteria by gene synthesis. The corresponding DNA fragment
was cloned between the NdeI and BamHI sites of the pET3a vector
(Merck Biosciences). For the creation of mutant ADK versions, we
used the QuickChange site-directed mutagenesis kit (Stratagene).
All constructs were verified by DNA sequencing. Protein expres-
sion in Rosetta 2(DE3)pLysS cells (Merck Biosciences) was
induced by the addition of 0.8 mM isopropyl-1-thio-b-d-galacto-
pyranoside to LB broth, and induction was maintained at 20C
for 20 hr. Protein was purified over a His-Select Ni2þ resin
(Sigma–Aldrich, Stockholm, Sweden) according to the manufac-
turer’s recommendations. After dialysis against 25 mM Tris-Cl
(pH 8.0), 0.5 mM EDTA, 10% glycerol, 1 mM DTT, and 200 mM
KCl, the purified recombinant ADKs were quantified via immuno-
lotting. A calibration curve was made with commercial human
ADK (NOVOCIB).Determination of ADK Activity in Wild-Type
and Mutant Recombinant Enzymes
Adenosine kinase activity of the recombinant proteins was assayed
essentially as described10 by enzymatic coupling of ADP formation
resulting from the ADK reaction, to NADH oxidation:
Adenosineþ ATP/AMPþ ADP
ADPþ PEP/ATPþ pyruvate
PyruvateþNADH/NADþ þ lactate
The assay mixture (final volume 500 ml) contained 50 mM Tris-
HCl (pH 7.4), 100 mM KCl, 0.5 mM MgCl2, 5 mM DTT, 100 mM
NADH, 500 mMphosphoenolpyruvate, 1 mMATP, 10 U/ml lactate
dehydrogenase (Sigma), 6.8 U/ml pyruvate kinase (Sigma), and
4 ng/ml of purified recombinant ADK. Reactions were started by
the addition of adenosine (ranging from 5–200 mM), and tracking
the decrease of absorbance at 340 nm (ε¼ 6.223103 M13 cm1)
on a Varian Cary 4000 Spectrophotometer (Agilent Technologies)
at 37C allowed measurement of NADH oxidation. The activity
was expressed as mmoles of adenosine consumed/min 3 mg
protein. All measurements were corrected for blanks containing
no adenosine.Results
SAHH Activity in Fibroblasts
An assay of S-adenosylhomocysteine hydrolase activitywas
established and used in fibroblasts from the two affected
Swedish siblings. SAHH activity was 39.6 nmol/hr/mg
protein for the brother and 30.8 nmol/hr/mg protein for
the sister (reference range: 32.3–37.9 nmol/hr/mg), thus
excluding SAHH deficiency.Exome Sequencing Identifies ADK as a Candidate
Gene in the Affected Swedish Siblings
Approximately 15 gigabases of sequence was generated
per individual, resulting in an approximately 125-fold
coverage of the 37 Mb targeted exome. More than 94%7, 2011
Table 2. Identification of Candidate Genes by Exome Sequencing
in the Two Siblings Affected by a Previously Undescribed IEM
Sibling 1 Sibling 2 Siblings 1 and 2
Dom Rec Hom Dom Rec Hom Dom Rec Hom
NS/SS/I 4,539 2,789 2,103 4,452 2,782 2,111 3,750 2,270 1,639
Not in
dbSNP131
424 62 26 422 49 21 213 28 13
Predicted to
be damaging
204 17 10 195 17 8 100 10 5
Gene processing for the affected pair of siblings in the Swedish family. Filtering
against databases of known variants (dbSNP 131) and application of the
recessive model for genes present in both siblings reduced the number of
genes more than 150-fold in all cases and almost 350-fold for the homozygous
model. Additional information from PolyPhen 2 further reduced the gene
count to a total of ten and five genes that overlapped between the two siblings
under the recessive and the homozygous models, respectively. The gene
containing the disease-causing mutations was present in the final list of five
genes. Abbreviations are as follows: Dom, R 1 heterozygous or homozygous
variant; Rec,R 1 homozygous orR 2 heterozygous variants; Hom,R 1 homo-
zygous variant; NS, nonsynonymous variant; SS, splice-site variant; I, coding
indel.
Figure 2. Sanger-Sequencing Traces of the Three ADKMissense
Mutations Causing Adenosine Kinase Deficiency
The first column shows results verifying the mutation detected by
exome sequencing in two affected Swedish siblings: a homozygous
C>A transversion at nucleotide 902 resulted in a p.Ala301Glu
amino acid substitution in adenosine kinase. The second and third
columns show the two homozygous mutations detected in two
Malaysian families with ADK deficiency: an A>C transversion at
nucleotide 653 caused a p.Asp218Ala amino acid substitution,
and a G>A transition at nucleotide 38 led to a p.Gly13Glu amino
acid substitution. In all cases, the control, wild-type sequences are
shown on top, a heterozygous parent is shown in the middle row,
and the homozygous mutations detected in the affected children
are displayed in the bottom row.of targeted bases were sufficiently covered to pass our
threshold for variant calling. Close to 130,000 variants
were identified per individual; more than 90% were
single-nucleotide variants, and fewer than 10% were in-
dels. Each sibling was found to have at least one NS/SS/I
variant in approximately 4,500 genes (dominant model)
and two or more NS/SS/I variants in 2,800 genes (recessive
model) (Table 2). Filtering against dbSNP build 131 to iden-
tify novel variants reduced the candidate gene pool 10-fold
for the dominant model and 50-fold for the recessive
model. When we considered only variants shared in both
siblings, the pool of candidate genes under a dominant
model was reduced to 213, and under our recessive model,
the number of candidate genes was reduced to 28. Using
PolyPhen 2 to predict the effect of a mutation generated
a list of ten genes with mutations predicted not to be
benign under the recessive model, a total reduction
of almost 450-fold. These genes were ADK (RefSeq
number NM_001123.3), FAM75C1 (NM_001145124),
FCGBP (NM_003890), FLG (NM_002016), FRG2B
(NM_001080998), FRG2C (NM_001124759), GGT1
(NM_013430), HRNR (NM_001009931), KRTAP9-9
(NM_030975), and ZNF141 (NM_003441). We had no
information of consanguinity in the family. However,
both parents originate from the same rural area in Sweden,
where genetic diversity is reduced. This increases the
probability that both parents are heterozygous carriers
for the same disease-causing variant. There were five genes
containing novel homozygous variants predicted to be
damaging. These were ADK (NM_001123.3), FAM75C1
(NM_001145124), FRG2B (NM_001080998), GGT1
(NM_013430), andHRNR (NM_001009931). Among these,
ADK, encoding the enzyme adenosine kinase, stood out
because blockage of this enzyme would be predicted to
disrupt the methionine cycle.The AmericValidation of Adenosine Kinase Deficiency
in the Affected Individuals
To validate our finding from exome sequencing, we used
DNA isolated from family members and analyzed exon
10 of ADK (National Center for Biotechnology Infor-
mation GeneID 132) by Sanger sequencing (Figure 2).
The previously identified c.902C>A transversion caus-
ing a p.Ala301Glu missense mutation was confirmed in
homozygous form in both affected siblings. Both parents
were heterozygous for the mutation, which was not
present in 105 unaffected Swedish controls. To verify
impaired adenosine kinase function in vivo, we measured
urinary adenosine levels. Frozen samples from 2001 were
retrospectively analyzed, and adenosine was elevated to
3.5 mmol/mol creatinine in the boy (reference value < 1)
and 9.9 mmol/mol creatinine in his sister (reference
value < 2). Analysis of a fresh sample from the affected
boy at 23 years of age showed an adenosine concentration
of 7.1 mmol/mol creatinine (reference value< 1). All other
purines and pyrimidines were essentially normal. DNA
from the two Malaysian families was subsequently ob-
tained, and all coding exons of ADK were analyzed by
Sanger sequencing. A c.653A>C transversion causing
a p.Asp218Ala mutation was found in homozygous form
in both siblings from the first family, and a c.38G>A
transition causing a p.Gly13Glu mutation was found in
homozygous form in both affected siblings from thean Journal of Human Genetics 89, 507–515, October 7, 2011 511
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Figure 3. Locations of the Mutated Residues in Human ADK
(A) Overall view of human ADK, showing the relative position of
the three mutated residues in the molecule and the catalytically
important Asp300. Two adenosine molecules, one occupying the
adenosine-binding site and the other the ATP-binding site, are de-
picted.
(B) Close-up image showing the position of Ala301. The mutated
amino acid sits between two crucial residues. Asp300 is ADK’s
active site responsible for the deprotonation the 50-OH group of
adenosine, which in turn attacks the gamma-phosphate of ATP.
Phe302 contributes to the binding of ATP. These three residues
are located in an alpha-helix between the two binding sites. Re-
placing Ala301, a residue with a short, neutral side chain, with glu-
tamic acid, containing a longer, charged side chain, is likely to
have deleterious consequences for enzyme function.
(C) Close-up image showing the location of residue Asp218 in the
central beta-sheet domain of the molecule. Asp218 sits at the N
terminus of beta-strand 11, which is part of a beta-sheet domain
that forms the core of the overall ADK structure.
(D) Close-up image showing the proximity of residue Gly13 to the
binding site for adenosine. The substitution of glycine, which has
only a hydrogen atom for a side chain, for glutamic acid, which
has a long, charged side chain, is likely to compromise the binding
of adenosine to ADK.
The numbering is based on the short isoform of ADK (isoform a;
transcript NM_001123.3; protein NP_001114.2), the crystal struc-
ture of which has been resolved.12
Figure 4. Adenosine Kinase Activity from Recombinant Wild-
Type and Mutant Enzymes
Recombinant forms of wild-type ADK, as well as ADK containing
each of the mutations detected in individuals with ADK defi-
ciency, were expressed in E. coli, purified, and tested for their
capacity to phosphorylate adenosine. The graph shows the
mean value þ 1 standard deviation of three independent mea-
surements carried out with 5 mM adenosine as described in the
Subjects and Methods. All mutants displayed significantly
impaired activity in comparison to the wild-type enzyme (two-
tailed Student’s t test). N.D. denotes not detectable; WT denotes
wild-type.second family (Figure 2). As expected, all parents carried
one mutation in heterozygous form. The locations of the
mutated residues were visualized in a model of human
ADK (Figure 3). All mutations were located in structurally
and/or functionally critical positions.
Assay of Adenosine Kinase Activity in Wild-Type
and Mutant Recombinant Enzyme
In order to test the functional effect of the mutations
found in our affected subjects, we expressed recombinant
forms of wild-type ADK, as well as ADK containing each
of the mutations, in E. coli, purified them, and tested
them for their capacity to phosphorylate adenosine over
a wide range of adenosine concentrations. The Km of
human ADK for adenosine at pH 7.5 has been estimated
to 0.15 mM, and maximum activity has been estimated at512 The American Journal of Human Genetics 89, 507–515, October0.5 mM. At higher concentrations, adenosine might also
occupy the ATP-binding site in ADK, which in turn leads
to an inhibition of enzyme activity.10 The activity of our
recombinant wild-type ADK closely resembled the pattern
previously described for the native form. The spectropho-
tometric method used does not allow one to accurately
assay ADK activity for adenosine concentrations below
5 mM, and therefore Km and Vmax values could not be
obtained. Nevertheless, the measurements obtained still
allowed us to effectively compare the activity of the
different mutants with that of the wild-type form. The
p.Ala301Glu mutant showed essentially no activity (Fig-
ure 4). The p.Asp218Ala mutant showed some residual
activity, amounting to about 20% of the wild-type at
5 mM adenosine. The p.Gly13Glu mutant showed traces
of activity (about 10% at 5 mM adenosine compared to
the wild-type).Discussion
Methionine is an essential amino acid that is not metabo-
lized via transamination as are most other amino acids.
The methionine cycle comprises a series of enzymatic
conversions, including adenosylation of Met by methio-
nine adenosyl transferases to AdoMet, donation of the
methyl group by one of many methyltransferases to a
wide range of methyl acceptors generating AdoHcy, and
subsequent hydrolysis by SAHH to generate adenosine
and the demethylated analog of Met, Hcy (Figure 1). Hcy7, 2011
is subsequently either remethylated back to Met or irre-
versibly transsulfurated via cystathionine to cysteine.
The siblings in our study had increased levels of Met,
AdoMet, and AdoHcy, indicating disruption of the methi-
onine cycle between AdoHcy and Hcy, but SAHH defi-
ciency was ruled out. Exome sequencing produced 10
(5 homozygous) candidate genes that conformed with a
recessive model and were shared in both siblings. Among
these, ADK stood out because it could be anticipated
to influence the function of SAHH (Figure 1). Adenosine
kinase (ADK; EC 2.7.1.20) is an abundant nucleoside
kinase that catalyzes the phosphorylation of the purine
nucleoside adenosine at the 50 position in an ATP-depen-
dent manner. Two isoforms of ADK have been identified
in humans. Both are identical except for a 17-residue
extension at the N terminus of the long isoform. The
short isoform is cytosolic, whereas the long isoform
recently has been localized to the nucleus.11 The crystal
structure of the human ADK (short isoform) has been
resolved.12 ADK catalyzes the phosphorylation of adeno-
sine to produce AMP.13,14 Adenosine is produced in the
methionine cycle together with Hcy via hydrolysis of
AdoHcy by SAHH. However, the equilibrium of this
reaction lies far in the direction of condensation,
producing rather than degrading AdoHcy. The thermody-
namics thus favor production of AdoHcy, and AdoHcy
will only be hydrolyzed if the reaction products, adeno-
sine and Hcy, are transported or removed enzymati-
cally.15 Thus, an adenosine increase due to impaired
removal by ADK would be predicted to result in increased
AdoHcy levels.
An Adk knockout mouse showing no prenatal pheno-
type but developing progressive microvesicular liver stea-
tosis from approximately postnatal day two has been
generated.16 The mice died within the first 8 days, and
on the basis of these results, ADK deficiency was
proposed as a putative causative factor for fatal neonatal
hepatic steatosis. However, the mice also displayed an
abnormal postnatal development from day 3, despite
normal feeding and nursing by the mothers; there
was a retardation in body weight development, a delay
in the time to eye opening, and intermittent periods of
apnea as well as an abnormal temperature regulation.
Both AdoMet and AdoHcy were significantly elevated
and the concentrations of total adenine nucleotides
were decreased in liver homogenates. Taken together,
the human and mouse phenotypes are strikingly similar,
although our affected individuals presented with
a predominantly neurological phenotype in combination
with moderate liver dysfunction, whereas the mice died
too early to allow a full neurological evaluation. During
embryonic development, adenosine is mainly degraded
into inosine by adenosine deaminase (ADA), but this
reaction is not pronounced in postnatal liver, where
ADA is expressed at very low levels.17 Postnatally, the
primary route of adenosine metabolism is believed to be
conversion to AMP by ADK.12,18 This probably explainsThe Americthe normal prenatal development and the postnatal onset
of symptoms in both mice and humans. Mutations in
ADA cause severe combined immune deficiency (SCID
[MIM 102700]), and increased levels of both adenosine
and 20-deoxyadenosine affect predominantly, but not
exclusively, the immune system.19
Several putative pathogenetic mechanisms might con-
tribute to the phenotype of ADK deficiency. Adenosine
is toxic to mammalian cells; for example, it is associated
with inhibition of the immune response, coronary va-
sodilation, delayed neurotransmission, and abnormal
hormone secretion. Adenosine is also considered a cell-
protective molecule and is increased during inflammation
and hypoxia, for example. Physiologically, the dephos-
phorylation of AMP by 50-nucleotidase to adenosine and
phosphate and the recycling of adenosine back to AMP
by ADK forms an ATP-consuming cycle that is considered
an important regulator of adenosine levels (the adenosine
futile cycle). Adenosine is a component of many vital
enzyme cofactors, such as FADH, NAD(P)H, and coen-
zyme A, and its biochemical effects also include activa-
tion of adenylate cyclase, inhibition of pyrimidine
biosynthesis, and diminution of phosphoribosyl pyro-
phosphate synthesis. In addition to toxic effects of
increased adenosine, decreased levels of adenine nucleo-
tides are likely to be detrimental for cellular metabolism
and mitochondrial function. As one example, AMP-acti-
vated protein kinase (AMPK) has been termed a ‘‘super
metabolic regulator’’ because of its effect on multiple
pathways, including those involved in glucose and fatty
acid metabolism.20
Adenosine accumulation leads to reversal of the SAHH
reaction, and this reversal causes increased AdoHcy levels
and disrupts the methionine cycle (Figure 1).21 Methyla-
tion involving AdoMet as the methyl group donor takes
place in all cells and this housekeeping metabolism com-
prises the methylation of a large variety of substrates,
including DNA, mRNA, tRNA, proteins, lipids, catechols,
indoles, guanidinoacetic acid, and many other com-
pounds. Mammalian methyltransferases are considered
to be subject to product inhibition by AdoHcy.22,23 Thus,
ADK deficiency is predicted to interfere with a wide range
of methyltransferase reactions.
Up to now, four IEMs have been known to present with
hypermethioninemia as a result of enzyme deficiencies
that directly interfere with Met or Hcy metabolism.5 The
enzymes deficient in these disorders are MAT I/III,
GNMT, SAHH, and CBS. Here we have described ADK
deficiency, a previously undescribed IEM that disrupts
the methionine cycle through a principally different
mechanism. The finding sheds light on a functional link
between the methionine cycle and adenosine metabolism,
and the disorder presents with a severe, slowly progressive
encephalopathy with epilepsy, macrocephalus and ab-
normal liver function. Hypermethioninemia is occasion-
ally identified incidentally, as well as in neonatal
screening programs aimed at diagnosing CBS deficiency.an Journal of Human Genetics 89, 507–515, October 7, 2011 513
Because ADK deficiency leads to grossly abnormal devel-
opment in affected children, awareness of this disorder
and discrimination against more benign conditions is
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